Opus Genetics completes enrollment in Phase 3 trial of OPGx-LCA5 gene therapy for LCA5 retinal disease
IRD•Phase 3 enrollment completed
Opus Genetics completed patient enrollment in a registrational Phase 3 trial of OPGx-LCA5 for LCA5-associated inherited retinal disease.
- No efficacy results have been presented; topline six-month efficacy data are expected by end of 2027.
- Dosing is slated to start in Q4 2026 following a run-in period that uses patients as their own control.
- The study is intended to support a potential BLA, with 12-month durability data planned during the review process.
